2.3. Analysis.
Comparison 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly versus sham for geographic atrophy (GA), Outcome 3: Safety: Development of MNV or exudative AMD at 1 year
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.